News Listing

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.

Until 1993, most clinical trial participants were men of European descent, leading to a lack of data on the safety and efficacy of treatments for women and diverse populations. Although ...

Sandwich, Kent, UK / 28th February 2024 / Discovery Park, Kent’s thriving life science community, is marking International Women’s Day by supporting women in business and tackling gender bias in healthcare. 

Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34m financing round.

Restore Harrow Green is once again expanding our footprint and opening another new branch, this time in Oxford!

We’re delighted to announce that Northern Balance has been awarded a multi-year contract for the proactive and reactive maintenance of the University of York’s suite of 400 plus laboratory balances.

In a recent blog post – AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production.

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

School engagement programme lights the spark for future innovators

IsomAb Ltd, a UK-based biotechnology company, announced today the closing of a £7.5 million (approximately US$9.4 million) Seed financing round, led by Broadview Ventures, with further backing from existing investor, SCVC and participation from MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF).
Founded in 2022 ...

AMSBIO, a leading provider of innovative products and services for the life sciences community, announces the launch of its Expanded Stem Cell Synergy Solutions.
Over the last two decades AMSBIO has established itself as a leading international supplier of solutions for streamlined and efficient ES/iPS Cell Culture using feeder-free StemFit® media and iMatrix recombinant laminin extracellular ...